CHMP Recommends Subcutaneous Form of Sanofi's Sarclisa and Four New Drugs

The Committee for Medicinal Products for Human Use recommended approval of a subcutaneous formulation of Sanofi's Sarclisa for multiple myeloma in late March 2026, part of a broader slate that included four novel drug candidates — a development that underscores how European regulators are racing to keep pace with US momentum in both biologics innovation and patient-friendly delivery systems [1]. The timing matters: as the first quarter closed, the biopharma sector logged a string of bolt-on deals and partnership announcements, including Sanofi's $180 million commitment to a California-based T cell engager startup, signaling that large-cap pharma is rebuilding portfolios around next-generation immunology platforms while simultaneously defending incumbent franchises through lifecycle management [2].

This is not simply a regulatory filing story. The subcutaneous formulation approval represents a critical defensive play in a hematologic oncology market where competition has intensified and where patient convenience increasingly drives formulary access and physician preference. Sarclisa, an anti-CD38 monoclonal antibody, competes directly with Johnson & Johnson's Darzalex — which already offers a subcutaneous option that has captured significant market share in both the US and Europe. The CHMP's recommendation levels the playing field for Sanofi in a multibillion-dollar indication where infusion time and site-of-care economics determine commercial success.

The broader CHMP slate included what the agency described as four new drugs, though details on therapeutic class, indication, and sponsor were not disclosed in the public notice [1]. One approval did surface publicly the same week: the FDA granted accelerated approval to Kresladi, the first gene therapy for severe Leukocyte Adhesion Deficiency Type I, a rare pediatric immune disorder caused by biallelic variants in the ITGB2 gene [3]. While the FDA and EMA operate on separate timelines, the confluence of approvals — spanning oncology, rare disease, and gene therapy — reflects a global regulatory apparatus working to accommodate diverse modalities under intensifying commercial and clinical pressure.

The Subcutaneous Migration and Infusion Economics

The shift from intravenous to subcutaneous administration in oncology biologics is not a minor formulation tweak — it is a billion-dollar market access battle. Subcutaneous delivery reduces infusion time from hours to minutes, lowers nursing resource requirements, and enables home or community-based administration. For payers, that translates to lower site-of-service reimbursement costs. For patients, it means fewer hospital visits and better quality of life. For manufacturers, it extends product lifecycle and defends market share against biosimilar encroachment.

Johnson & Johnson's Darzalex SC, approved in Europe in 2020 and the US shortly thereafter, demonstrated the commercial power of this transition. The subcutaneous version rapidly overtook the IV formulation, accounting for the majority of new starts within 18 months of launch. Sanofi's delay in bringing Sarclisa SC to market allowed Darzalex to entrench itself as the standard of care in frontline and relapsed/refractory multiple myeloma regimens. The CHMP recommendation, while late to the game, is essential for Sanofi to remain competitive in triplet and quadruplet regimens that anchor myeloma treatment in Europe.

What institutional investors should note: the oncology biologics market is bifurcating between sponsors who can execute on formulation innovation and those who cannot. Patents on the underlying molecule matter less than operational execution on delivery systems, real-world evidence generation, and physician education. This is a commercial and supply chain competency, not just an R&D story.

Sanofi's Parallel Pivot: Rebuilding Immunology Through Deals

The same week the CHMP slate emerged, Sanofi announced a partnership valued at up to $180 million with an undisclosed California-based startup focused on T cell engagers, a modality that redirects a patient's own immune cells to target and destroy cancer cells [2]. The deal is part of Sanofi's broader effort to rebuild presence in immuno-oncology and immunology, sectors where the company has historically underperformed relative to peers like Bristol Myers Squibb, Merck, and Roche.

T cell engagers represent one of the most active deal categories in biopharma today. The modality — which includes bispecific antibodies and other formats — has demonstrated clinical efficacy across hematologic malignancies and solid tumors, with several products already approved and dozens in late-stage development. The competitive intensity is high: Novartis announced a deal worth up to $2 billion to acquire Excellergy and its next-generation anti-IgE candidate, positioning it as a successor to Xolair, the blockbuster allergy and asthma drug [2]. That transaction, announced the same week, underscores how large-cap pharma is willing to pay steep premiums for differentiated immunology assets.

For Sanofi, the T cell engager partnership is both a growth investment and a hedge. The company's oncology portfolio remains thin relative to its size, and its immunology franchise — anchored by Dupixent — faces inevitable biosimilar pressure within the next decade. Building a pipeline of next-generation immunomodulators is strategic necessity, not opportunistic diversification.

Gene Therapy Approvals and the Regulatory Flexibility Debate

While the Sarclisa recommendation dominated European headlines, the FDA's approval of Kresladi for severe LAD-I on March 26, 2026, offers a useful parallel narrative [3]. Kresladi, developed through ex vivo gene editing of a patient's own hematopoietic stem cells, is the first approved therapy for a disease that previously had no FDA-sanctioned treatment beyond allogeneic stem cell transplant — an option available only to patients with an HLA-matched sibling donor.

The FDA granted accelerated approval based on a single-arm, open-label trial that measured increases in neutrophil CD18 and CD11a cell surface expression, disease-specific biomarkers indicative of immune restoration. The agency explicitly cited "significant regulatory flexibilities" in both chemistry, manufacturing, and control review and clinical assessment, acknowledging the constraints of rare disease development where large randomized trials are not feasible [3].

This regulatory posture — flexible, pragmatic, willing to approve on surrogate endpoints — is critical for the gene therapy sector, which has struggled with high development costs, small patient populations, and uncertain commercial returns. For institutional investors, the approval signals that both FDA and EMA remain committed to enabling curative modalities despite recent scrutiny over accelerated approval pathways and post-marketing confirmatory trial compliance.

Cross-Border Regulatory Convergence and Divergence

The near-simultaneous activity at FDA and EMA in late March 2026 highlights both convergence and divergence in global regulatory strategy. On convergence: both agencies are advancing approvals in rare disease and oncology, prioritizing unmet need and accepting smaller datasets where justified. On divergence: the specific products, timelines, and evidentiary standards differ, creating complexity for sponsors managing global development programs.

For Sanofi, the CHMP recommendation for Sarclisa SC will likely be followed by European Commission approval within two to three months, standard timing for positive CHMP opinions. The company has not disclosed US filing timelines for the subcutaneous formulation, though FDA approval is presumed to be either already secured or imminent given the competitive imperative. The lack of public disclosure on US status suggests Sanofi may be managing a phased launch strategy, prioritizing Europe to offset Darzalex's entrenchment in the US market.

For gene therapy developers, the FDA's Kresladi approval may prompt EMA to accelerate its own rare disease gene therapy reviews, particularly for conditions with no alternative therapies. The European regulatory framework has historically been more conservative on surrogate endpoints and post-marketing obligations, but competitive pressure to attract biopharma investment and manufacturing capacity may drive convergence.

The Plocamium View

The CHMP's Sarclisa SC recommendation is not a catalyst for Sanofi equity — it is a defensive necessity that prevents further erosion in a competitive oncology franchise. The real signal is the simultaneous deployment of capital into T cell engagers, a modality where Sanofi has been conspicuously absent. The $180 million California partnership is a down payment on a longer-term portfolio rebuild, and we expect Sanofi to announce additional immunology and oncology deals before year-end as the company seeks to derisk its post-Dupixent revenue profile.

The broader theme institutional allocators should track: large-cap pharma is bifurcating into two cohorts. The first — companies like Novartis, Bristol Myers Squibb, and AbbVie — are executing aggressive M&A and licensing strategies to acquire next-generation modalities at high valuations. The second — companies like Sanofi and GSK — are playing catch-up, acquiring assets at what appear to be reasonable prices but with higher technical and commercial risk. The performance gap between these cohorts will widen over the next 24 months as late-stage pipeline density becomes the primary driver of market multiples.

On gene therapy, Kresladi's approval is a proof point that FDA's accelerated pathway remains functional despite political and media scrutiny. The agency's explicit language around regulatory flexibility is intentional signaling to developers that rare disease programs will not be held to the same evidentiary bar as large-indication trials. That is a green light for continued investment in curative modalities, particularly in pediatric genetic disorders where transplant is the only alternative. The European parallel will be EMA's response to similar programs in the next six months — if the agency matches FDA's flexibility, gene therapy capital flows will shift toward Europe. If not, the US will remain the primary approval pathway.

The subcutaneous biologics migration in oncology is a permanent shift, not a trend. Any IV-only product in hematology or solid tumor indications will face formulary and physician resistance within three years. Sponsors without SC formulations in development will either partner, acquire, or exit the category. This is a supply chain and operations story as much as a clinical one — the winners will be those who can manufacture, distribute, and support at-home or community administration at scale.

The Bottom Line

The CHMP's March 2026 recommendation slate — headlined by Sarclisa SC but inclusive of four undisclosed novel drugs — is a snapshot of a global biopharma sector in transition. Incumbents are defending franchises through lifecycle innovation while simultaneously acquiring next-generation platforms to offset looming patent cliffs. Regulators are accommodating rare disease and curative therapies through flexible approval pathways, creating opportunity for developers who can navigate small datasets and surrogate endpoints. And the competitive bar for patient-friendly delivery systems is rising, with subcutaneous formulations becoming table stakes in oncology.

For institutional capital, the playbook is clear: overweight sponsors with dense late-stage pipelines across multiple modalities, underweight those relying on single-product franchises or IV-only biologics, and selectively allocate to gene therapy developers with rare disease assets in markets where no alternative therapy exists. The first quarter of 2026 closed with a flurry of regulatory and deal activity — the second quarter will reveal which companies can execute on commercial launches and which are merely managing decline.

---